Adult-to-adult living donor liver transplantation

Shimul A Shah MD, Gary A Levy MD, Lesley D Adcock MD, Gary Gallagher RN, David R Grant MD

Abstract

Liver transplantation (LT) is a highly successful therapy for patients with end-stage liver failure. Over the past 10 years, the demand for this procedure has steadily increased in Canada, primarily due to an epidemic of hepatitis B- and C-related liver disease (1-3). Unfortunately, deceased donor (DD) organ rates have not substantially increased during the same period and this has resulted in a growing gap between the need for LT and the supply of donor organs.

In Canada, there are currently over 700 patients waiting for a liver graft. All LT centres in Canada have experienced increasing wait times and increasing number of deaths on the waiting list. In 2004, 96 patients died in Canada while on the waiting list for a liver graft. In the greater Toronto area alone, more than 70 people died in 2004 during their workup for LT or while waiting for a donor organ. The waiting time for a DD transplant grew to more than three years for most blood groups and it was increasingly rare for a blood group O recipient to be transplanted while the patient was still well enough to wait at home.

Living donor liver transplantation (LDLT) was introduced in 1989 to overcome the severe shortage of size-matched DD organs for pediatric recipients (4). Given the increasing shortage of DD grafts for adults in North America and Europe, living donation (LD) was now being explored as a potential solution to the shortage of DD organs for adults also. Adult-to-adult LDLT consisted of the removal of the right lobe, which carried a higher risk of morbidity and mortality compared with the resection of the left lateral lobe which is usually performed on children (Figure 1).

More than 2000 LDLTs (right and left lobe grafts) have been performed throughout the world. There have been a number of deaths after LD (5,6) and the risk of death is estimated to be 0.2% to 0.5% with left lobe donation and 0.3% to 1% with right lobe donation. Ethical concerns have been raised and the long-term success of right lobe donor hemipatectomy will depend on the safety and efficiency of the procedure.

Enthusiasm in the United States has waned since 2001 after the death of a living donor in New York City, New York (5). This is despite relatively stagnant DD volumes and increasing number of patients on the waiting list. In 2004, roughly 350 LDLTs were performed in the United States; this number has remained relatively constant since 2002. Proper documentation of complications, uniform standards and dedicated LD protocols will be necessary to monitor progress and growth in LDLT.

The shortage of donor organs is more acute in Canada than in the United States due to our much lower DD rates. Although we are still in the early stages of experience with LDLT in Canada, there is already evidence of a positive impact (Figure 2). In Toronto, where the donor shortage is particularly acute, LDLT now accounts for 40% of total adult LT volumes (Figure 3).

LD has several potential advantages. The surgery can be performed at an optimal time before the recipient’s health deteriorates unduly; furthermore, the recipient receives a high-quality organ due to thorough donor evaluation and shorter cold ischemic time. The donor has a unique opportunity to restore good health to a close friend or family member (7,8). Because the liver regenerates, long-term

Key Words: Cirrhosis; Liver transplantation; Living donor; Morbidity; Right heptectomy


The present review outlines the principles of living donor liver transplantation, donor workup, procedure and outcomes. Living donation offers a solution to the growing gap between the need for liver transplants and the limited availability of deceased donor organs. With a multidisciplinary team focused on donor safety and experienced surgeons capable of performing complex resection/reconstruction procedures, donor morbidity is low and recipient outcomes are comparable with results of deceased donor transplantation.

Transplantation hépatique à donneur vivant d’adulte à adulte

Le présent article de synthèse rappelle les principes de la transplantation hépatique à donneur vivant et décrit la préparation du donneur, les étapes de l’intervention et le pronostic. La greffe de foie provenant d’un donneur vivant offre une solution à la pénurie grandissante d’organes pour les transplantations et à la difficulté d’obtenir des organes provenant de cadavres. Grâce à une équipe pluridisciplinaire déterminée à assurer la sécurité du donneur et à des chirurgiens expérimentés et capables de réaliser de complexes interventions de résection et de reconstruction, la morbidité est faible chez les donneurs et l’issue du traitement chez les receveurs se compare aux résultats obtenus avec les greffons provenant de cadavres.
Shah et al

Figure 1) Anatomy of right lobe, living donor hepatectomy. Reproduced/adapted from reference 28

Figure 2) Ratio of living donor liver transplants to deceased donor liver transplants in adults living in Canada from 1995 to 2004

Figure 3) Adult liver transplant (LT) volumes in Toronto. LDLT Living donor liver transplantation

provide a letter of support from his/her attending doctor before starting the workup.

The duration of workup is determined by the availability of health care resources, the donor's schedule and the complexity of the donor's health issues. We review all potential donors in workup at a multidisciplinary conference that includes surgeons, medical doctors, nurses, social workers and transplant coordinators. Any concerns are discussed in an open manner during this meeting.

The intended recipient must consent to LD; some patients are reluctant to do this because of concerns about potential harm to the donor. At our centre, recipients of LD grafts must satisfy the criteria for LT or meet expanded criteria that are within predefined protocols or clinical trials. Recipients of LD grafts must consent to sharing information about the cause of harm to the donor. At our centre, recipients of LD grafts must have a potential LD.

To proceed with LD, there must be an agreement among the donor, recipient and the medical team that this surgery is appropriate. We will not perform LDLT if the medical and surgical team believe that the potential for harm outweighs the benefits. Unusual ethical issues may be taken to the Transplant Ethics Committee for review and advice. Because the physicians and members of the transplant team also act as moral agents, we believe that the final decision to perform the LDLT must rest with the transplant doctors. If the team decides that LD is inappropriate, we routinely offer to arrange referrals to other programs for second opinions.

Donor safety is the main priority guiding the timing of surgery. It is important to have a well-rested and experienced surgical team for LT to maximize safety. Thus, LD is not performed as an emergency procedure at our centre.

Costs and long-term consequences of LD remains a controversial issue in the transplant community. In Ontario, the Ontario Ministry of Health and Long-Term Care (Ontario
Health Insurance Plan (OHIP)) supports the direct costs of liver donation. However, neither OHIP nor the hospital will compensate donors for indirect costs such as time lost from work, travel expenses, or outpatient mediation costs. If a donor travels from another country to donate; only assessment tests, physician and hospital costs are covered by the recipient’s OHIP. Travel costs are not covered nor are the costs of any investigations or follow-up performed in their country of origin. At the University of Toronto, we are attempting to follow all donors and recipients for up to 10 years to monitor long-term safety.

LIVING DONOR ASSESSMENT

All living donors are deemed suitable for surgery after completing an evaluation process that includes an initial health-screening survey, blood tests, viral serology, imaging studies and medical and psychiatric assessments by health care professionals independent of the transplantation team. These consultations provide potential donors with an opportunity to confidentially opt out or decline liver donation for medical, social or personal reasons without having to provide an explanation to the intended recipient or to the transplant team.

Routine liver biopsy before LD remains controversial; we have elected to perform liver biopsy selectively in patients in whom liver steatosis is suspected and in those with serum liver enzyme abnormalities (9). Donors with a body mass index greater than 35 kg/m² are not evaluated until they have completed a successful weight loss program. Absolute exclusion criteria include any underlying medical condition that is considered to increase the risk for complications, ABO incompatibility, positive hepatitis serology, underlying liver disease, inadequate graft size, steatosis greater than 10% and abnormal biliary anatomy (eg, branches to left lobe arising from right duct).

Triphasic computerized tomography is performed to assess arterial and venous anatomy; to assess whether the middle hepatic vein should stay in the donor or the recipient; and to estimate the volume of the whole liver, right lobe and remaining liver using OSIRIS imaging software (Digital Imaging Unit, University Hospital of Geneva, Switzerland). The liver resection plane is assessed to ensure that the residual liver weight to total liver weight ratio would be 30% or greater. The estimated graft-to-recipient weight ratio is calculated by dividing the volume of the right lobe by the recipient’s weight; a ratio of at least 0.8% is considered acceptable. Magnetic resonance cholangiography has been used to assess biliary anatomy since 2001 (10,11).

A multistep consent process involving two different surgeons on separate occasions is used, during which the operative procedure and potential complications are described in detail. Donors are informed that the risk of morbidity and mortality is 40% and 0.5%, respectively. Donors are supported in whichever decision they make. The assessment for LD is a dynamic process. At any stage, the potential donor or the health care team may decide that it is not suitable to proceed with liver donation.

Currently, only approximately 20% of donors who indicate an interest in LD actually undergo the procedure. Between April 2000 and December 2005, 554 patients were evaluated for liver donation at the Toronto General Hospital (Toronto, Ontario); during this time period, 166 (30%) of these patients underwent hepatectomy. The common causes of dropout or refusal after preliminary evaluation at our centre are listed in Table 1.

<table>
<thead>
<tr>
<th>Reason</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Under evaluation or underwent living donation</td>
<td>201</td>
<td>36</td>
</tr>
<tr>
<td>Donor decision</td>
<td>65</td>
<td>12</td>
</tr>
<tr>
<td>Cadaveric transplant for recipient</td>
<td>43</td>
<td>8</td>
</tr>
<tr>
<td>Alternate donor selected</td>
<td>34</td>
<td>6</td>
</tr>
<tr>
<td>Donor unsuitable</td>
<td>32</td>
<td>6</td>
</tr>
<tr>
<td>Recipient medically unsuitable for transplant</td>
<td>27</td>
<td>5</td>
</tr>
<tr>
<td>Recipient died before transplant</td>
<td>23</td>
<td>4</td>
</tr>
<tr>
<td>Size discrepancy</td>
<td>22</td>
<td>4</td>
</tr>
<tr>
<td>Liver steatosis</td>
<td>18</td>
<td>3</td>
</tr>
<tr>
<td>Donor anatomy unsuitable</td>
<td>14</td>
<td>3</td>
</tr>
<tr>
<td>Other</td>
<td>75</td>
<td>13</td>
</tr>
<tr>
<td>Total</td>
<td>554</td>
<td>100</td>
</tr>
</tbody>
</table>

RIGHT LOBE LIVING DONOR HEPATECTOMY

Patients donated one to two units of autologous blood within one month of the planned surgery date. Prophylactic antimicrobial (cefazolin, metronidazole) and anti-deep vein thrombosis (DVT; heparin 5000 U subcutaneously) therapy was initiated immediately before surgery. Pneumatic compression stockings were used routinely over the past year to reduce the risk of DVT. Epidural analgesic delivery was offered to all donors.

Surgery was performed through a right subcostal hockey-stick incision (12). An intraoperative cholangiogram with fluoroscopy was performed first to verify biliary anatomy; surgery was aborted in four donors (3%) because of abnormal biliary anatomy which was only detected by cholangiography. The right hepatic artery and right portal vein(s) were mobilized.

The right lobe was mobilized off the inferior vena cava; the right hepatic vein and accessory right hepatic veins exceeding 8 mm in diameter were preserved for revascularization in the recipient. The Hydro-Jet Dissector (ERBE, Germany) and the Cavitron Ultrasonic Aspirator (CUSA Excel, Valleylab, USA) were used to transect the liver parenchyma along the plane of the middle hepatic vein which was retrieved with the graft when it provided the dominant venous drainage to the right lobe. A red blood cell scavenging device was used routinely. A cholangiogram was performed at the end of the procedure.

Donors were managed in an intensive care step-down unit for the first 48 h and then in a regular surgical ward. Complete blood counts, coagulation profile and serum liver tests were monitored daily. Patients were given parenteral magnesium and phosphate infusions routinely until tolerating diet and then were transitioned and discharged home on oral magnesium and phosphate as required (13-15). DVT prophylaxis continued with heparin 5000 U subcutaneously and sequential compression stockings while in hospital and with low molecular weight heparin (dalteparin sodium injection; Pharmacia, Canada) 5000 U subcutaneously daily for six weeks after discharge. All patients under went routine Doppler ultrasound of the abdomen on the third postoperative day to assess vessel integrity and flow. Donors were followed up with routine laboratory investigations and abdominal ultrasound at one month, three months, six months and then annually after surgery.
DONOR OUTCOMES
A crude complication rate of 31% (54 events in 174 donors) was reported in a review of 12 studies of right lobe liver donors (16). The overall complication rate in our first 101 cases in Toronto was 37% (Table 2) (3). No patient had suffered life-threatening organ dysfunction or residual disability. The complication rate during the first 30 days postoperatively was significantly lower than in the later one-half of our experience. All donors are currently alive and well, and have returned to their normal daily activities.

The earliest most common serious complication (3) was postoperative bleeding which occurred in four patients on postoperative day 1. All were taken to the operating room. The source of bleeding in all four cases was a small artery in the hilar plate; this complication has since been avoided because we started routinely oversewing this area.

Other early complications included bile leak (3%), subphrenic or pleural collections requiring drainage (3%) and pulmonary emboli (1%). Two of the three bile leaks were treated with endoscopic retrograde cholangiopancreatography, stent placement and papillotomy; the other was treated with a percutaneous drain. Temporary percutaneous drainage of a subphrenic or pleural effusion was required in three patients. Three patients required reclosure of a partial fascial dehiscence located at the junction of the midline and subcostal portion of the incision. Late complications have included incisional hernia (n=6), pneumonia (n=2), late pulmonary embolism (n=2) and partial bowel obstruction (n=1).

RECIPIENT OUTCOMES
LDLT provides an option to avoid the risk of death while waiting for a DDLT. One-year survival after LDLT is similar to DDLT. However, if one compares survival of patients from the time of listing who are waiting for a DDLT or who undergo DDLT with patients who undergo LDLT, there is a survival advantage as early as 12 months (Figure 4). Reported rates of survival after both LDLT and DDLT is between 86% to 88% (1,17-20). Survival statistics for LDLT should be interpreted with caution; in many cases, patients are selected with the best chance of favourable outcome, minimal cirrhosis or portal hypertension, and shorter waiting times. Direct comparisons between DD and LDLT can only be made if the degree of liver disease is stratified and accounted for in the analyses (eg, Model for End-Stage Liver Disease).

Specific problems inherent to LDLT comprise a spectrum of complications that are still poorly understood. There has been a higher rate of bile duct complications in live donor recipients compared with DD recipients (approximately 20% versus approximately 5%) but most of these complications have been resolved with nonsurgical management (19,21-24); these problems include bile leaks from the cut surface of the transected liver, biliary strictures and anastomotic leaks. Hepatic artery thrombosis is also more common in LDLT, with rates of 1% to 7% (20,25,26). Small-for-size syndrome is an important entity with an unknown frequency and clinical course in LDLT. Its mechanism is poorly understood because it can occur despite adequate volume calculations and body weight assessments pre-LT. Graft dysfunction of suboptimally drained segments (usually segments 5 and 8) can account for this debilitating syndrome. We prefer a graft-to-recipient ratio of greater than 0.8 in all LDLT and believe that additional venous drainage through the middle hepatic vein may alleviate congestion of the graft in the medial sector and lead to better function (2).

FUTURE PROSPECTS
Balancing donor-risk relative to the recipient outcome is an ongoing task in the evolution of LDLT. Other important issues that require further study include: hypercoaguable states in donors after hepatectomy, small-for-size grafts, venous outflow

**TABLE 2**
Total complications of right lobe living donor liver transplantation classified by severity at the University of Toronto, Toronto, Ontario

<table>
<thead>
<tr>
<th>Complication*</th>
<th>n (%)</th>
<th>Operative intervention (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade I</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary tract infection/recatheterization</td>
<td>4 (4)</td>
<td>–</td>
</tr>
<tr>
<td>Arrythmia</td>
<td>1 (1)</td>
<td>–</td>
</tr>
<tr>
<td>Depression</td>
<td>2 (2)</td>
<td>–</td>
</tr>
<tr>
<td>Grade II</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incisional hernia or repair</td>
<td>9 (9)</td>
<td>Operative (9)</td>
</tr>
<tr>
<td>Wound infection</td>
<td>5 (5)</td>
<td>–</td>
</tr>
<tr>
<td>Bleeding (reoperation)</td>
<td>4 (4)</td>
<td>Operative (4)</td>
</tr>
<tr>
<td>Subphrenic/pleural collection</td>
<td>4 (4)</td>
<td>Endoscopic (4)</td>
</tr>
<tr>
<td>Bile leak</td>
<td>3 (3)</td>
<td>Endoscopic (3)</td>
</tr>
<tr>
<td>Pulmonary emboli</td>
<td>2 (2)</td>
<td>–</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>2 (2)</td>
<td>–</td>
</tr>
<tr>
<td>Partial bowel obstruction</td>
<td>1 (1)</td>
<td>–</td>
</tr>
<tr>
<td>Grade III</td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>37 (37)</td>
<td>20 (20%)</td>
</tr>
</tbody>
</table>

*Grade of complication determined by Clavien's classification (27)
obstruction, hepatic artery thrombosis, liver steatosis and timing. As allocation systems evolve to ensure that limited organs benefit those patients at a greatest risk of death (eg, Model for End-Stage Liver Disease), LDLT may become an avenue to provide a liver graft to someone who would not ordinarily qualify for a DD organ.

CONCLUSIONS
LDLT is an effective life-saving procedure for patients with end-stage liver disease. We predict that the demand for right lobe LDLT in North America, specifically Canada, will continue to increase because of the critical shortage of donor organs. Although LDLT has been performed with low morbidity at high-volume transplant centers, it remains a daunting operation with unique surgical and ethical challenges. Comprehensive documentation of complications and long-term follow-up will continue to be required to define donor-risk and to advance the field.

ACKNOWLEDGEMENTS: The authors thank Robert Smith for data and statistical support.

REFERENCES